Calithera Biosciences, Inc. – NASDAQ:CALA
Founder-led company
Calithera Biosciences stock price today
$0.03
+0.02
+29900%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in 20 minutes
Calithera Biosciences stock price monthly change
-100.00%
month
Calithera Biosciences stock price quarterly change
-100.00%
quarter
Calithera Biosciences stock price yearly change
-100.00%
year
Calithera Biosciences key metrics
Market Cap | 487 |
Enterprise value | N/A |
P/E | -0.01 |
EV/Sales | N/A |
EV/EBITDA | 0.52 |
Price/Sales | N/A |
Price/Book | 0.01 |
PEG ratio | N/A |
EPS | -0.90 |
Revenue | N/A |
EBITDA | -43.76M |
Income | 422K |
Revenue Q/Q | N/A |
Revenue Y/Y | -100% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCalithera Biosciences stock price history
Calithera Biosciences stock forecast
Calithera Biosciences financial statements
| Mar 2022 | 0 | -13.84M | |
|---|---|---|---|
| Jun 2022 | 0 | 10.22M | |
| Sep 2022 | 0 | -10.07M | |
| Dec 2022 | 0 | 14.12M |
| 2025 | 247.98M | -10.53M | -4.25% |
|---|
Analysts Price target
Financials & Ratios estimates
| Mar 2022 | 50236000 | 53.37M | 106.24% |
|---|---|---|---|
| Jun 2022 | 45558000 | 10.30M | 22.62% |
| Sep 2022 | 37083000 | 10.69M | 28.84% |
| Dec 2022 | 28676000 | 8.28M | 28.89% |
| Mar 2022 | -16.01M | 0 | 1.13M |
|---|---|---|---|
| Jun 2022 | -11.26M | -110K | 8.49M |
| Sep 2022 | -7.73M | 0 | 15K |
| Dec 2022 | -8.59M | -23K | 4K |
Calithera Biosciences alternative data
| Aug 2023 | 8 |
|---|---|
| Sep 2023 | 8 |
| Oct 2023 | 8 |
| Nov 2023 | 8 |
| Dec 2023 | 8 |
| Jan 2024 | 8 |
| Feb 2024 | 8 |
| Mar 2024 | 8 |
| Apr 2024 | 8 |
| May 2024 | 8 |
| Jun 2024 | 8 |
| Jul 2024 | 8 |
Calithera Biosciences other data
57.46%
+2.61%
of CALA is owned by hedge funds
42.44M
+1.79M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2023 | 0 | 1172 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | PAKIANATHAN DEEPIKA director | Common Stock | 1,172 | $0.39 | $452 | ||
Sale | ORFORD KEITH officer: Director | Common Stock | 48,190 | $0.88 | $42,407 | ||
Sale | ORFORD KEITH officer: Director | Common Stock | 30,000 | $0.86 | $25,710 | ||
Purchase | MOLINEAUX SUSAN director, officer.. | Common Stock | 100,000 | $0.85 | $84,700 | ||
Purchase | DRACHMAN JONATHAN G director | Common Stock | 200,000 | $0.86 | $172,000 | ||
Purchase | MOLINEAUX CHRISTOPHER officer: SR. VP, DEVELOPMENT | Common Stock | 100,000 | $0.85 | $84,700 | ||
Sale | ORFORD KEITH director | Common Stock | 51,810 | $0.84 | $43,520 | ||
Sale | ORFORD KEITH officer: CHIEF MEDICAL OFFICER | Common Stock | 2,447 | $6 | $14,682 | ||
Sale | BVF PARTNERS L P/IL 10 percent owner | Common Stock, $0.0001 par value | 2,283,598 | $6 | $13,701,588 | ||
Sale | WONG STEPHANIE officer: See Remarks | Common Stock | 5,000 | $8 | $40,000 |
| Patent |
|---|
Grant Filling date: 1 Feb 2021 Issue date: 28 Jun 2022 |
Grant Filling date: 8 May 2020 Issue date: 7 Jun 2022 |
Grant Filling date: 8 Nov 2017 Issue date: 5 Apr 2022 |
Grant Filling date: 27 Sep 2019 Issue date: 28 Dec 2021 |
Application Filling date: 4 Mar 2021 Issue date: 25 Nov 2021 |
Grant Filling date: 27 Sep 2019 Issue date: 16 Nov 2021 |
Application Filling date: 5 Oct 2020 Issue date: 23 Sep 2021 |
Application Filling date: 20 Jan 2021 Issue date: 26 Aug 2021 |
Grant Filling date: 20 Jun 2019 Issue date: 3 Aug 2021 |
Application Filling date: 1 Nov 2018 Issue date: 17 Jun 2021 |
| Quarter | Transcript |
|---|---|
| Q3 2022 14 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 15 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 10 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 31 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Susan M. Molineaux Ph.D. (1954) Founder, Chief Executive Officer, Pres & Director | $806,950 |
-
What's the price of Calithera Biosciences stock today?
One share of Calithera Biosciences stock can currently be purchased for approximately $0.03.
-
When is Calithera Biosciences's next earnings date?
Unfortunately, Calithera Biosciences's (CALA) next earnings date is currently unknown.
-
Does Calithera Biosciences pay dividends?
No, Calithera Biosciences does not pay dividends.
-
How much money does Calithera Biosciences make?
Calithera Biosciences has a market capitalization of 487.
-
What is Calithera Biosciences's stock symbol?
Calithera Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "CALA".
-
What is Calithera Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Calithera Biosciences?
Shares of Calithera Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Calithera Biosciences's key executives?
Calithera Biosciences's management team includes the following people:
- Dr. Susan M. Molineaux Ph.D. Founder, Chief Executive Officer, Pres & Director(age: 71, pay: $806,950)
-
Is Calithera Biosciences founder-led company?
Yes, Calithera Biosciences is a company led by its founder Dr. Susan M. Molineaux Ph.D..
-
How many employees does Calithera Biosciences have?
As Jul 2024, Calithera Biosciences employs 8 workers.
-
When Calithera Biosciences went public?
Calithera Biosciences, Inc. is publicly traded company for more then 10 years since IPO on 2 Oct 2014.
-
What is Calithera Biosciences's official website?
The official website for Calithera Biosciences is calithera.com.
-
Where are Calithera Biosciences's headquarters?
Calithera Biosciences is headquartered at 343 Oyster Point Boulevard, South San Francisco, CA.
-
How can i contact Calithera Biosciences?
Calithera Biosciences's mailing address is 343 Oyster Point Boulevard, South San Francisco, CA and company can be reached via phone at +65 08701000.
Calithera Biosciences company profile:
Calithera Biosciences, Inc.
calithera.comExchange:
NASDAQ
Full time employees:
8
Industry:
Biotechnology
Sector:
Healthcare
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
343 Oyster Point Boulevard
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001496671
ISIN: US13089P5070
CUSIP: 13089P101
